Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

Video

Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses atypical responses with immunotherapies in melanoma.

Compared to cytotoxic chemotherapy, responses can sometime be delayed with immunotherapy agents, says Mitchell.

On the first response assessment after immunotherapy, the tumor may appear larger or the same size as it was before treatment. This may be because the immunotherapy can take a longer time to work, or it could be due to immunotherapy-related inflammation in the tumor. This type of inflammation can sometimes look radiographically like a larger tumor, but a subsequent response assessment will reveal good tumor shrinkage and response, says Mitchell.

Related Videos
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute